Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
ÌÇÐÄ´«Ã½
Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML Daver, N., Lee, K., Choi, Y., Montesinos, P., Jonas, B. A., Arellano, M. L., Borate, U., Watts, J. M., Koller, P. B., Jung, C., Sohn, S., Fathi, A. T., Vachhani, P., Podoltsev, N. A., Salamero, O., Yoon, S., Lee, J., Mannis, G. N., Tan, S., Mukherjee, S., Erba, H., Shin, H., Platzbecker, U., Tormo, M., Tam, E., Berkahn, L., Bernal, T., Haney, D., Hu, J., Sinha, R., Khan, N., Victory, V., Rice, W. G., Bejar, R. ELSEVIER. 2024: 4255-4258View details for
View details for